Huimin Zhao
Contact Information:
e-mail:
phone: (217) 333-2631
fax: (217) 333-5052
215 Rogers Adams Lab
MC-712, Box C-3
600 S. Mathews Ave.
Urbana, IL 61801
Centennial Chair
B.S., University of Science and Technology of China, 1992
Ph.D., California Institute of Technology, 1998
- Special Recognition Award, Dow Chemical Company, 1999, 2000
- Collins Scholar, Academy of Excellence in Engineering Education, College of Education, University of Illinois, UC, 2001
- CAREER Award, National Science Foundation, 2004
- Excellence in Teaching Award, School of Chemical Sciences, University of Illinois, UC, 2004
- Xerox Award for Faculty Research, College of Engineering, University of Illinois, UC, 2005
- Young Investigator Award, Dupont, 2005
- Beckman Fellow, Center for Advanced Study, University of Illinois, UC, 2005-2006
- Helen Corley Petit Scholar, College of Liberal Arts and Sciences, University of Illinois, UC, 2006-2007
- University Scholar, University of Illinois, UC, 2007
- Young Investigator Award, American Chemical Society, 2008
- Excellence in Advising Award, College of Engineering, University of Illinois, UC, 2008
Protein Engineering and Metabolic Engineering
Research in the Zhao group is focused on protein engineering and
metabolic engineering. The overall research theme is
to use directed evolution in combination with rational
design to create proteins, receptors, biosynthetic pathways,
and whole cells with improved or novel functions, followed by
detailed biochemical and biophysical characterizations. There
are dozens of ongoing projects in the lab, which can be generally
grouped into four different areas as described below. It should
be noted that although the following projects are all application-driven,
we are also very interested in addressing fundamental
questions related to protein structure-function relationship,
enzyme catalysis, molecular recognition, gene regulation, and
immunology.
Industrial Biotechnology and Bioenergy
We successfully used directed evolution and rational design approaches to develop a novel phosphite dehydrogenase based NAD(P)H regeneration system by (1) improving the enzyme activity toward NADP by 1000-fold, (2) increasing the overall activity by 6-fold, and (3) increasing the thermostability by more than 22,000-fold. The resulting technology was patented and licensed to BASF and Biocatalytics. Based on this new cofactor regeneration method, we are developing new in vitro and in vivo methods for cost-effective production of xylitol, one of the twelve platform chemicals that the Department of Energy has identified for the emerging biorefinery industry. In addition, we are interested in converting renewable feedstock such as corn stovers into biofuels including ethanol, butanol, and other long-chain alcohols. Using a combination of protein engineering, metabolic engineering, bioinformatics, and functional genomics, we attempt to address key roadblocks in fermentative production of chemicals and biofuels from renewable feedstock, including limited range and poor efficiency of sugar utilization, relatively low product yield, productivity and titer, and low tolerance level to products and/or substrates.
Drug Discovery and Development
We are using protein and metabolic engineering tools to overproduce phloroglucinol,
an important pharmaceutical intermediate in E. coli. Several biosynthetic
pathways and enzymes such as type I polyketide synthases
and type III polyketide synthases
have been characterized and engineered. In addition, novel enzymes involved in
arylamine oxygenation have been discovered and characterized using various biochemical
and biophysical methods such as HPLC, EPR, LC-MS, and protein crystallography.
In addition, in collaboration with the Metcalf, van der Donk, Kelleher, and Satish
groups at University of Illinois, we are characterizing and engineering a
new class of natural products, so-called phosphonic acids, many of which show
antimicrobial, anticancer, and fungal and herbicidal activities. We recently
cloned the gene cluster involved in the synthesis of fosfomycin, an FDA-approved
antibiotic, and are now attempting to overproduce it in both E. coli and
yeast. We are also interested in another phosphonic acid compound, FR-900098,
an anti-malarial agent, among many others. In addition to overproducing these
antibiotics, we are also using combinatorial biosynthesis and directed evolution
approaches to generate novel derivatives of phosphonic acids with the hope of
discovering new antibiotics with improved biological function.
Synthetic Biology and Gene Therapy
We are using directed evolution and rational design approaches to create a variety of transcription factor based gene switches and gene circuits to precisely control the gene expression levels in mammalian cells and animals. Such gene switches and circuits are invaluable tools for gene therapy, tissue engineering, functional genomics, therapeutic protein production, and stem cell engineering. In collaboration with world-leading scientists including Drs. John Katzenellenbogen, William Helfrich, Pierre Chambon, and Daniel Metzger, we are evaluating these tools in both mammalian cells and transgenic animals and applying them to address many different biomedical challenges. In addition, we are creating homing endonuclease based gene scissors that can introduce specific double strand breaks in a target gene. Such tools represent a new therapeutic regime for gene therapy. Two genetic diseases of particular interest are cystic fibrosis and sickle cell anemia.
MHC Engineering and Immunotherapy
We are applying protein engineering and yeast cell surface display to create yeast based artificial antigen presenting cells for analysis and engineering of human class
II major histocompatibility complex (MHC) molecules for diagnostic and therapeutic applications. Based on this new system, we recently developed a new method for identifying CD4+ T-cell epitopes, which is a critical but often difficult limiting step for pathogenesis studies and a wide range of immunological and clinical applications. We are now further optimizing this system and extending it to other biomedical applications such as vaccine development, tumor antigen identification, T-cell staining, and treatment of autoimmune diseases.
Selected Publications
H. Zhao, "Directed Evolution of Novel Protein Functions," Biotechnology and Bioengineering, 98, 313-317 (2007).
J. Lee and H. Zhao, "Identification and Characterization of a Flavin:NADH Reductase (PrnF) Involved in the Novel Two-component Arylamine Oxygenase," Journal of Bacteriology, 189, 8556-8563 (2007).
T. Johannes, R. Woodyer, and H. Zhao. "Efficient Regeneration of NADPH using
an Engineered Phosphite Dehydrogenase," Biotechnology and Bioengineering, 96,
18-26 (2007).
H. Zhao and W. Zha, "In vitro 'Sexual' Evolution through the PCR-based
Staggered Extension Process (StEP)," Nature Protocols, 1, 1865-1871 (2006).
R. Woodyer, Z. Shao, P. M. Thomas, N. L. Kelleher, J. A. V. Blodgett, W. M.
Metcalf, W. A. van der Donk, and H. Zhao, "Heterologous Production of
Fosfomycin and Identification of the Minimal Fosfomycin Biosynthetic Cluster," Chemistry & Biology,
13, 1171-1182 (2006).
W. Zha, S. Rubin-Pitel, and H. Zhao, "Characterization of the Substrate
Specificity of PhlD, a Type III Polyketide Synthase from Pseudomonas fluorescens," J.Bio.
Chem., 281, 32036-32047 (2006).
M. Simurdiak, J. Lee, and H. Zhao, "A New Class of Arylamine Oxidases:
Evidence that p-Aminobenzoate N-oxidase is a Diiron Enzyme and Further
Mechanistic Studies," ChemBioChem, 7, 1169-1172 (2006).
T. Johannes and H. Zhao, "Directed Evolution of Enzymes and Biosynthetic
Pathways," Current Opinion in Microbiology, 9, 261-267 (2006).
J. Lee and H. Zhao, "Mechanistic Studies on the Conversion of Arylamines
into Arylnitro Compounds by Arylaminopyrrolnitrin Oxygenase: Identification
of Intermediates and Kinetic Studies," Angew. Chem. Int. Ed., 45, 622-625
(2006).
Z. Chen and H. Zhao, "A Highly Sensitive Selection Method for Directed
Evolution of Homing Endonucleases," Nucleic Acids Research, 33, e154 (2005).
K. Chockalingam, Z. Chen, J.A. Katzenellenbogen, and H. Zhao, "Directed
Evolution of Specific Receptor-Ligand Pairs for Use in the Creation of Gene
Switches," Proc. Nat. Acad. USA, 102, 5691-5696 (2005).
Z. Chen and H. Zhao, "Rapid Creation of a Novel Protein Function by
in vitro Co-evolution," J. Mol. Bio., 348, 1273-1282 (2005).